Healthcare provider profile · identity verified

Edgar Ochoa, MD

Family Practice · FONTANA, CA · NPI 1780751685

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	491	254
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	324	58
Amlodipine Besylate	Amlodipine Besylate	249	133
Losartan Potassium	Losartan Potassium	238	116
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	226	27
Lisinopril	Lisinopril	181	101
Metformin Hcl	Metformin Hcl	179	107
Pantoprazole Sodium	Pantoprazole Sodium	171	94
Tramadol Hcl	Tramadol Hcl	153	31
Levothyroxine Sodium	Levothyroxine Sodium	140	79
Rosuvastatin Calcium	Rosuvastatin Calcium	139	80
Omeprazole	Omeprazole	119	79
Glipizide	Glipizide	109	62
Lorazepam	Lorazepam	107	12
Tamsulosin Hcl	Tamsulosin Hcl	106	54
Potassium Chloride	Potassium Chloride	99	57
Metformin Hcl Er	Metformin Hcl	89	44
Pradaxa	Dabigatran Etexilate Mesylate	87	29
Albuterol Sulfate Hfa	Albuterol Sulfate	85	57
Gabapentin	Gabapentin	84	50
Ezetimibe	Ezetimibe	83	32
Metoprolol Succinate	Metoprolol Succinate	81	36
Alprazolam	Alprazolam	75	15
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	74	35
Furosemide	Furosemide	63	37
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	36
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	63	13
Atenolol	Atenolol	62	35
Simvastatin	Simvastatin	62	36
Hydrochlorothiazide	Hydrochlorothiazide	61	35
Ibuprofen	Ibuprofen	59	36
Ozempic	Semaglutide	59	14
Trazodone Hcl	Trazodone Hcl	59	32
Jardiance	Empagliflozin	57	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	57	30
Clopidogrel	Clopidogrel Bisulfate	53	26
Lactulose	Lactulose	50	19
Metoprolol Tartrate	Metoprolol Tartrate	50	26
Alendronate Sodium	Alendronate Sodium	48	30
Temazepam	Temazepam	46	suppressed
Clonazepam	Clonazepam	44	suppressed
Acyclovir	Acyclovir	43	16
Finasteride	Finasteride	42	21
Acetaminophen-Codeine	Acetaminophen With Codeine	41	suppressed
Carvedilol	Carvedilol	40	22
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	40	18
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	39	18
Prednisone	Prednisone	37	29
Estradiol	Estradiol	36	15
Triamcinolone Acetonide	Triamcinolone Acetonide	35	19
Eliquis	Apixaban	34	12
Terazosin Hcl	Terazosin Hcl	34	22
Azithromycin	Azithromycin	33	25
Humulin N	Insulin Nph Human Isophane	33	18
Spiriva Respimat	Tiotropium Bromide	33	suppressed
Baclofen	Baclofen	30	suppressed
Fentanyl	Fentanyl	30	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	30	12
Allopurinol	Allopurinol	29	14
Bisoprolol Fumarate	Bisoprolol Fumarate	29	15
Fluticasone Propionate	Fluticasone Propionate	29	13
Meloxicam	Meloxicam	29	15
Ondansetron Odt	Ondansetron	29	18
Montelukast Sodium	Montelukast Sodium	28	17
Pioglitazone Hcl	Pioglitazone Hcl	28	14
Naproxen	Naproxen	27	16
Nystatin	Nystatin	27	13
Rizatriptan	Rizatriptan Benzoate	27	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	27	13
Humulin R	Insulin Regular, Human	25	16
Hydralazine Hcl	Hydralazine Hcl	25	15
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	24	12
Fluoxetine Hcl	Fluoxetine Hcl	23	12
Mupirocin	Mupirocin	22	19
Nortriptyline Hcl	Nortriptyline Hcl	22	suppressed
Liraglutide	Liraglutide	21	12
Colchicine	Colchicine	20	15
Famotidine	Famotidine	20	13
Lidocaine	Lidocaine	20	12
Mirtazapine	Mirtazapine	20	12
Doxepin Hcl	Doxepin Hcl	19	11
Methocarbamol	Methocarbamol	19	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	19	19
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	18	18
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Pregabalin	Pregabalin	16	suppressed
Promethazine Hcl	Promethazine Hcl	16	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	16	suppressed
Victoza 2-Pak	Liraglutide	16	suppressed
Alvesco	Ciclesonide	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Cephalexin	Cephalexin	13	12
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Naloxone Hcl	Naloxone Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Victoza 3-Pak	Liraglutide	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	11
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Oxazepam	Oxazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error